देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
Dinoprost trometamol
Ceva Santé Animale
QG02AD01
Dinoprost trometamol
5 milligram(s)/millilitre
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle, Pigs
dinoprost
Hormone
Authorised
2004-07-30
Health Products Regulatory Authority 17 December 2020 CRN009ZLZ Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Enzaprost 5 mg/ml Solution for injection for cattle and pig 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Dinoprost (as trometamol) 5 mg EXCIPIENTS: Benzyl alcohol (E1519) 16.5 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear colourless solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle: cows, heifers. Pigs: sows, gilts. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES The product is indicated for its luteolytic effects in cattle and pigs. CATTLE The luteolytic effect of the product can be exerted in following therapeutic uses: 1. Oestrus synchronisation. 2. Treatment of sub-oestrus or silent heat in cows which have a functional corpus luteum, but do not express behavioural oestrus. 3. Induction of abortion until day 120 of pregnancy. 4. Induction of parturition. 5. For the aid in the treatment of chronic metritis or pyometra where there is a functional or persistant corpus luteum. PIGS 1. Induction of parturition from day 111 of pregnancy. 2. Post partum use: reduction of the weaning to oestrus interval (WOI) and the weaning to fertile service interval (WFSI) in sows with puerperal problems such as metritis in herds with reproductive problems. 4.3 CONTRAINDICATIONS Do not treat animals if they suffer from either acute or subacute disorders of the vascular system, gastro-intestinal tract or respiratory system. Do not administer to pregnant animals, unless it is desirable to induce parturition or interruption of pregnancy. Do not use in cases of known hypersensitivity to the active substance or to any of the excipients. Health Products Regulatory Authority 17 December 2020 CRN009ZLZ Page 2 of 5 4.4 SPECIAL WARNINGS FOR पूरा दस्तावेज़ पढ़ें